INCY Share Price

Open 124.66 Change Price %
High 124.91 1 Day 0.48 0.39
Low 124.02 1 Week -0.15 -0.12
Close 124.39 1 Month -15.25 -10.92
Volume 1174416 1 Year 49.96 67.12
52 Week High 153.15
52 Week Low 68.03
INCY Important Levels
Resistance 2 125.22
Resistance 1 124.88
Pivot 124.44
Support 1 123.90
Support 2 123.56
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
AKRX 33.09 1.13%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ACAS 17.99 0.39%
WRES 0.09 28.57%
More..
NASDAQ USA Top Gainers Stocks
PGRX 0.06 100.00%
SPIR 0.02 100.00%
LOCM 0.09 50.00%
RITT 0.03 50.00%
CLNT 4.50 30.81%
CALI 3.45 29.21%
WRES 0.09 28.57%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
ULTR 0.05 -37.50%
More..

Incyte Corporation (NASDAQ: INCY)

INCY Technical Analysis 2
As on 25th Apr 2017 INCY Share Price closed @ 124.39 and we RECOMMEND Buy for LONG-TERM with Stoploss of 102.19 & Strong Sell for SHORT-TERM with Stoploss of 133.40 we also expect STOCK to react on Following IMPORTANT LEVELS.
INCY Target for April
1st Target up-side 145.48
2nd Target up-side 153.76
3rd Target up-side 162.04
1st Target down-side 121.86
2nd Target down-side 113.58
3rd Target down-side 105.3
INCY Other Details
Segment EQ
Market Capital 2323686912.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.incyte.com
INCY Address
INCY
Experimental Station
Route 141 & Henry Clay Road
Wilmington, DE 19880
United States
Phone: 302-498-6700
INCY Latest News
Interactive Technical Analysis Chart Incyte Corporation ( INCY NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Incyte Corporation
INCY Business Profile
Incyte Corporation (Incyte) is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs to treat serious unmet medical needs. Its advanced compound, JAKAFI (ruxolitinib), also known as INCB18424 and INC424, is an oral Janus associated kinase (JAK) inhibitor used for the treatment for patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF and post-essential thrombocythemia MF. The Company has a second oral JAK1 and JAK2 inhibitor, LY3009104 (INCB28050), which is subject to a collaboration agreement with Eli Lilly and Company in which Lilly received worldwide development and commercialization rights for the compound for inflammatory and autoimmune diseases. In November 2011, JAKAFI became commercially available in the United States and is being marketed in the United States.